Table 1 Baseline characteristics.
PGA < 33.5 µmol/mmol creatinine | PGA ≥ 33.5 µmol/mmol creatinine | Total | P value | |
|---|---|---|---|---|
N | 75 (75%) | 25 (25%) | 100 | |
Gender, Female | 28 (37.3%) | 15 (60%) | 43(43%) | 0.047 |
Age (IQR) | 78 (62, 92) | 84 (71, 92) | 79.5 (67,87) | 0.11 |
BMI ≤ 18 kg/m2 | 2/24 (8.3%) | 0/3 (0%) | 2 (2%) | 1.0 |
Hypertension | 45 (60%) | 17 (68%) | 62 (62%) | 0.475 |
Ischemic heart disease | 17 (22.7%) | 4 (16%) | 21 | 0.478 |
Congestive heart failure | 12 (16%) | 3 (12%) | 15 | 0.755 |
Diabetes mellitus | 24 (32%) | 13 (52%) | 37 | 0.073 |
S/P Stroke | 24 (32%) | 10 (40%) | 34 | 0.465 |
Dyslipidemia | 29 (38.7%) | 13 (52%) | 42 | 0.242 |
Atrial fibrillation | 12 (16%) | 7 (28%) | 19 | 0.239 |
Chronic kidney disease | 9 (12%) | 5 (20%) | 14 | 0.33 |
α Blockers | 14 (18.7%) | 3 (12%) | 17 (17%) | 0.55 |
β Blockers | 22 (29.3%) | 7 (28%) | 29 | 0.899 |
Calcium channel blockers | 16 (21.3%) | 4 (16%) | 20 | 0.564 |
ACEI/ARBs | 31 (41.3%) | 8 (32%) | 39 | 0.407 |
Diuretics | 13 (17.3%) | 8 (32%) | 21 | 0.119 |
Antipsychotics | 6 (8%) | 6 (24%) | 12 | 0.053 |
Platelet aggregation inhibitors | 33 (44%) | 9 (36%) | 42 | 0.841 |
Anticoagulants | 13 (65%) | 7 (28%) | 20 | 0.248 |
Statins | 21 (28%) | 2 (8%) | 23 | 0.04 |
